Is Shilpa Medicare a Cancer Giant – Important Notes from 2020 Annual Report

Reading Time: 5 minutes

Written By: JST Investments

Source linkTwitter Profile | JST Investments Website

Shilpa Medicare Logo

Source: Stockinforce

Important Takeaways from Shilpa Medicare 2020 AR

  • Amongst the leading APIs and Formulations manufacturers with strong capabilities in the therapeutic area of oncology and non-oncology.
  • Supplies 30+ oncology APIs to the USA, Europe, Japan, etc (10yrs+ experience in regulated markets).
  • Aims to commercialize 3-4 molecules per year.
  • In the process of debottlenecking oncology production blocks by enhancing capacity by 40-70%.
  • Sale of non-oncology APIs: Ambroxol (Mucolytic agent) in Europe and Tranexamic Acid and Ursodeoxycholic acid in India.
  • Formulations: 16 injectable dosage forms, 19 oral solid dosage forms under SML & 13 Formulations under SML’s wholly-owned subsidiary Shilpa Therapeutics Private Limited.

 

How Big is Cancer?

Cancer is the second leading cause of death.

According to a WHO, report cancer caused an estimated 9.6 million deaths in 2018. 

Globally, about 1 in 6 deaths is due to cancer. Approximately 70% of deaths from cancer occur in low- and middle-income countries.

Shilpa Medicare Plant

Source: Moneycontrol

Of the 15,267 assets across all phases of development, about 34% are oncolytic, up from 30% in 2013. 

  • The company has forayed into Biologics, Oral Dissolving Films, and Transdermal Patches.
  • While stepping into FY2021, acquired FTF Pharma, an integrated drug development company.
  • Biosimilars: 4 of the top 15 products in the pipeline.
  • A combo line at the upcoming facility in Bangalore for Oral.
  • Disintegrating Films and Transdermal patches will be commissioned soon.
  • 265+ scientists | 357 patents filed with 47 granted.
  • The formulation product pipeline consists of 61 with 38 approvals.
  • Highlights of the year gone by one ANDA & 6 FTF in pipeline | Good CashFlow Conversion.
  • Gross block up 13% YoY to 875crs; CWIP: 482crs; Intangible Assets under development: 182 Crs.
Also Read on FinMedium:  A Complete Guide on Financial Derivatives | A Money-Making Machine? ~ The Finance Magic - Stock Market | Personal Finance
Shilpa Medicare ANDA Filings
  • Form 483 with 15 observations at the Jadcherla, Telangana formulation plant.
  • Shilpa Medicare oncology APIs segment has delivered as per plan and will continue to progress based on our attractive pipeline and diversified base of intermediates.
  • 1st company in India to launch ODF and among the first few in Nano.
Shilpa Medicare Strategy
  • Capacity: 120m tablets & capsules | 15m Liquid & Lyophilised Injections | 2m Prefilled Syringes | 350 tonnes API
  • Biologics Capabilities of Shilpa Medicare: Need to monitor.
  • Interesting Development
    • Launched green tea films – a revolutionary technology 
    • Formed a new subsidiary to manufacture “Recombinant Human Albumin (RHS), recombinant peptides, analogs, and polymers” 

 

API Manufacturing: What is the opportunity size for India and Shilpa Medicare?

India is a source of about 20% of the world’s generic drugs supply.

Drug and pharma exports from India rose 11.7% on year to touch $19.15 billion in the 11 months to February 2020.

The global API market is expected to reach US$ 245 billion (6.1% CAGR) by 2024.

  • Regulatory Filings Summary: Progressing towards more complex generics | Product Development & License fees: 135crs.
Shilpa Medicare Revenue Medicare
Geographical Revenue breakup
  • On the Biologics front: Shilpa Medicare is in an advanced stage for setting up of a world-class biologics manufacturing facility for Monoclonal antibodies and biologics in Belur, Dharwad.
  • The facility consists of two production lines for Drug Substance. The first, second lines are currently in qualification and expected to be completed by 2020.
  • Shilpa Medicare is forging ahead with clinical trials on 1 no MAb, 1 nos fusion protein, and 1 nos NBE during the course of the coming financial year, while 1 other is expected to complete preclinical studies. (combined market size ~$20 billion.)
Also Read on FinMedium:  Mutual Fund KYC - All You Need To Know About Mutual Fund KYC Process

Shilpa Medicare Products Portfolio

Image: Shilpa Medicare Products Portfolio | Source: Stockinforce

  • 2 more are expected to be added in the next financial year to the clinical trial pipeline, with market size of about $12 billion.
  • Complex Capital Structure: A common theme in pharmaceutical companies.
  • 1754 permanent employees | median increase of 9.53% YoY
  • Constant promoter Shareholding: 53.80%

Also Watch: Shilpa Medicare Diversification Plans

Read more Company Analysis here.


Source linkTwitter Profile | JST Investments Website

Cover Image: Stock in Force

Disclaimer: The opinions expressed in this publication are those of the authors. They do not purport to reflect the opinions or views of the FinMedium or its members. The presentation of material therein does not imply the expression of any opinion whatsoever on the part of the FinMedium concerning the legal status of any company, country, area, or territory or of its authorities. For more info. please read our ToU & Privacy Policy here. If you have any concerns regarding this post, please reach out to us at finmedium@gmail.com


JST Investments

JST Investments

JST Investments is a Mumbai-based investment firm that believes in long-term wealth creation. It's a brainchild of Aditya Kondawar, Aditya Shah, and Anish Moonka.
Please Share Now :)